Abstracts Archive - Page 198 of 2607 - ACR Meeting Abstracts

Abstract Number: 2658 • ACR Convergence 2024
Hypovitaminosis D in Lupus Nephitis
Alicia Yupe¹, Emma Puron Gonzalez², Esteban Salatino³, Jessica Santana⁴, Montserrat Ochoa⁴, Rosa Elena Cervantes-Ramirez⁵, Eli Marisol Saldaña⁶, gabriel Calderon⁷, Brissia Ceniceros⁸, Ulices de la Cruz⁹, Monica Meza¹⁰ and Sergio Cerpa Cruz⁶, ¹Facultad de Ciencias Médicas, Universidad de San Carlos de Guatemala., Guatemala, Guatemala, ²UDEM/ITESM, San Pedro Garza Garcia, Mexico, ³Faculty of Medical Sciences, Universidad de San Carlos de Guatemala., Guatemala, GU, ⁴Hospital Civil "Fray Antonio Alcalde", Guadalajara, Mexico, ⁵Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico, Distrito Federal, Mexico, ⁶Hospital Civil de Guadalajara, Guadalajara, Mexico, ⁷Hospital Civil de Guadalajara, Monterrey, Mexico, ⁸Hospital Civil de Guadalajara, Torreón, Coahuila de Zaragoza, Mexico, ⁹Hospital Civil "Fray Antonio Alcalde", Guadalajara, ¹⁰Centro Universitario de Ciencias de la SAlud, Guadalajara
Background/Purpose: The prevalence of vitamin D deficiency is higher in patients with systemic lupus erythematosus (SLE) compared to the healthy population, and recent studies have…
Abstract Number: 2583 • ACR Convergence 2024
Apremilast Reduces Axial Inflammation in Patients with Psoriatic Arthritis as Assessed by CANDEN MRI Scoring: Results from a Phase 4 Study
Mikkel Ostergaard¹, Walter Maksymowych², Robert Lambert², Mikael Boesen³, Guillermo J. Valenzuela⁴, Michael R. Bubb⁵, Olga Kubassova⁶, Xenofon Baraliakos⁷, Carlo Selmi⁸, Stephen Colgan⁹, Yuri Klyachkin¹⁰, Cynthia Deignan¹¹, Zhenwei Zhou¹¹ and Philip Mease¹², ¹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ²University of Alberta, Edmonton, AB, Canada, ³Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁴Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, ⁵University of Florida, Gainesville, FL, ⁶Image Analysis Group, Philadelphia, PA, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁸Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, ⁹Amgen, Halton Hills, ON, Canada, ¹⁰Amgen, Lexington, KY, ¹¹Amgen Inc., Thousand Oaks, CA, ¹²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Apremilast is an oral phosphodiesterase-4 inhibitor with a unique immunomodulatory mechanism of action and is approved for the treatment of psoriatic arthritis (PsA). Although…
Abstract Number: 2651 • ACR Convergence 2024
Vasculitis Associated with VEXAS Syndrome
Megan Sullivan¹, Kambiz Kalantari², Carolyn Mead-Harvey³, Yael Kusne⁴, Mrinal Patnaik², Abhishek Mangaonkar², Ronald Go², Daniel Montes², Kaaren Reichard², Horatiu Olteanu², Melanie Bois², Alexander Hines², Julio Sartori-Valinotti⁵, Kenneth Warrington² and Matthew Koster², ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Scottsdale, AZ, ⁴Mayo Clinic, Phoenix, AZ, ⁵Mayo Clinic, Rohester, MN
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently defined clinical entity that causes hematologic and autoinflammatory symptoms. Since its initial description…
Abstract Number: 2675 • ACR Convergence 2024
Which Arthralgia Patients at Risk for RA Benefited from Treatment with Methotrexate?; Results from the TREAT EARLIER Trial
Stijn Claassen¹, Quirine Dumoulin², Kasper Glas³, Esmeralda Molenaar⁴, Hanna van Steenbergen¹ and Annette van der Helm-van Mil⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ³Reumazorg Zuid West Nederland, Goes, The Netherlands, Goes, Zeeland, Netherlands, ⁴Groene Hart Ziekenhuis, Gouda, The Netherlands, Gouda, Zuid-Holland, Netherlands, ⁵LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: A one-year methotrexate treatment in CSA has been shown to induce sustained reduction in subclinical inflammation during 2-years follow-up. We aim to study if…
Abstract Number: 2668 • ACR Convergence 2024
Do Levels of anti-Jo1 Autoantibodies Have a Prognostic Role? Longitudinal Assessment of anti-Jo1 and HisRS Protein Levels in a Cohort of anti-Jo1 Positive Patients with Anti-synthetase Syndrome
Silvia Cavalli¹, Fabricio Espinosa-Ortega², Ryan A. Adams³, Lauren Guy³, Charlotta Preger⁴, Càtia Fernandes-Cerqueira⁵, Roberto Caporali⁶, Ingrid Lundberg⁷ and Antonella Notarnicola⁸, ¹University of Milan, Milan, Milan, Italy, ²Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet; Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³aTyr Pharma, 3545 John Hopkins Court, Suite 250, San Diego, CA, ⁴Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet;5Structural Genomics Consortium, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ⁵4Dcell, Montrueil, Ile-de-France, France, ⁶Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁷Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁸Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: The anti-Jo1 autoantibody (aJo1), targeting the histidyl-tRNA synthetase (HisRS) protein, is the most common diagnostic biomarker of the anti-synthetase syndrome (ASSD). So far, conflicting…
Abstract Number: 2480 • ACR Convergence 2024
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial
Robert Spiera¹, Robert Lebovics², Sarah Bray³, Rachel E. Gurlin⁴, David Jayne⁵ and Peter Merkel⁶, and ADVOCATE Study Group, ¹Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ²Hackensack Meridian University Health System, Hackensack, NJ, ³Amgen Ltd, Cambridge, United Kingdom, ⁴Amgen Inc., Mountain View, CA, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: In the phase 3 ADVOCATE trial, 45.2% and 42.1% of patients in the avacopan and prednisone taper groups, respectively, had active ear, nose, or…
Abstract Number: 2678 • ACR Convergence 2024
History of Cutaneous Lupus Promotes Blood and Skin Interferon Signatures in SLE Patients
Svenja Henning¹, Lam Tsoi², Craig Dobry², Celine Berthier², Benjamin Klein², Amy Hurst², Rachael Wasikowski³, Johann Gudjonsson² and J. Michelle Kahlenberg², ¹University of Groningen, Groningen, Netherlands, ²University of Michigan, Ann Arbor, MI, ³Michigan, Dept. of Dermatology, Ann Arbor, MI
Background/Purpose: Cutaneous lupus (CLE) can present in isolation or as one of the most common manifestations of systemic lupus erythematosus (SLE). Interferon (IFN) stimulated genes…
Abstract Number: 2608 • ACR Convergence 2024
Evolution of Rheumatoid Arthritis Pharmacotherapy: A Ten-Year Analysis of Biologic and Targeted Synthetic DMARD Use and Its Predictors in a National Sample of Rheumatology Practices
Jing Li¹, Gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: The last decade has seen dramatic shifts in pharmacotherapy for rheumatoid arthritis (RA) with the increasing availability of biologic and targeted synthetic DMARDs (b/tsDMARDs).…
Abstract Number: 2620 • ACR Convergence 2024
Education and Medication Access Needs in Rheumatology Patients Starting New Medications: Quality Improvement Data from a Pharmacist Intervention
Vivianne Allsop¹, Brett Glasheen², Stephanie Khong², Anthony Minjarez³, Natalie Morlan², Kami Roake², grant Cannon⁴, Nadia Grant² and Jessica A Walsh⁵, ¹University of Utah, South Jordan, UT, ²University of Utah, Salt Lake City, UT, ³Salt Lake City Veterans Affairs Health, Salt Lake City, UT, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT
Background/Purpose: Disease modifying anti-rheumatic drugs are a cornerstone of rheumatology care. Patient education and support is required to optimize outcomes and minimize access barriers. Pharmacists…
Abstract Number: PP05 • ACR Convergence 2024
Reunion with Forgotten Relationships and Memories
Noriko Okochi¹, Eiji Oishi², Kaoru Mitsuyama³, Emi Sorimachi³, Shiho Bando⁴, Yuka Hirama⁵, Nobuyuki Yajima⁶ and Masaaki Mori⁷, ¹Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, ²Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan, ³Institute of Neuropsychiatry, Tokyo, Tokyo, Japan, ⁴Ota-ku Children and Families Support Center, Ota-ku, Tokyo, Japan, ⁵Asada Ladies Clinic, Shinagawa, Japan, Tokyo, Japan, ⁶Showa-Universtiy of Medicine, Tokyo, Japan, ⁷Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Paediatric rheumatic diseases are complex experiences for children. For children whose language skills are still undeveloped, it is difficult for them to put their…
Abstract Number: PP16 • ACR Convergence 2024
Utilization of My Knee Notes for Enhanced Healthcare Management
Tien Sydnor-Campbell, Medically Retired, Philadelphia, PA
Background/Purpose: Living with chronic knee issues for 40 years has been incredibly challenging. My knee pain began as early as 6th grade but got overlooked…
Abstract Number: PP07 • ACR Convergence 2024
My Journey with Diffuse Scleroderma and Interstitial Lung Disease: A Pharmacist’s Perspective
Joseph Washington, Cencora, Washington, DC
Background/Purpose: Since my diagnosis with diffuse scleroderma and ILD, I have balanced the roles of patient and young pharmacist. A duality that has surely impacted…
Abstract Number: PP03 • ACR Convergence 2024
How Completing a Systematic Literature Review Improved How I Research My Own Rheumatoid Arthritis and Comorbidities
Shelley Fritz, Global Healthy Living Foundation, Kalaheo, HI
Background/Purpose: Twelve years ago, I was diagnosed with rheumatoid arthritis (RA). Initially, I was hopeful that the first biologic DMARD would slow the disease and…
Abstract Number: PP14 • ACR Convergence 2024
Support Groups and Chronic Illness: Finding Social Support Among Peers
Alexandra Blumhorst¹ and Estela Mata-Carcamo², ¹Looms for Lupus, Silver Spring, MD, ²Looms for Lupus, Irwindale, CA
Background/Purpose: Like many lupus patients, my journey has been long, complex, and difficult. I began experiencing symptoms in 2019. Over the next five years, I…
Abstract Number: PP13 • ACR Convergence 2024
Bridging the Gap from Pediatric to Adult Rheumatology Care
Natasha Trehan, University of Ottawa, Take a Pain Check Foundation, Markham, ON, Canada
Background/Purpose: When I was 13, life took an unexpected turn with a diagnosis of Juvenile Idiopathic Arthritis (JIA). Overnight, my world transformed into a cycle…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].